ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group
InventorsAdrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
Life of this patent
Estimating the term…
Abstract
An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
Claims22
-14. (canceled)
A method of killing a cancer cell having C3d complement protein on the surface thereof in a subject, the method comprising administering to the subject (1) an anti-C3d antibody or antibody fragment comprising a heavy chain variable region comprising
- SEQ ID NO:
- 1 as heavy chain complementary determining region-1 (CDRH1);
- SEQ ID NO:
- 2 as heavy chain complementary determining region-2 (CDRH2);
- and
- SEQ ID NO:
- 3 or 4 as heavy chain complementary determining region-3 (CDRH3);
- and
- a light chain variable region comprising
- SEQ ID NO:
- 5 as light chain complementary determining region-1 (CDRL1);
- SEQ ID NO:
- 6 as light chain complementary determining region-2 (CDRL2);
- and
- SEQ ID NO:
- 7 as light chain complementary determining region-3 (CDRL3), and
- (2) an antibody or antibody fragment to a cell surface protein other than C3d selected from the group consisting of an anti-CD33 antibody or antibody fragment, an anti-CD38 antibody or antibody fragment, an anti-EGFR antibody or antibody fragment, and an anti-ERBB2 antibody or antibody fragment,
- wherein administration of the antibody or antibody fragment to a cell surface protein other than C3d induces formation of C3d complement protein the surface of the cancer cell.
-38. (canceled)
Dependencies are inferred from the claim text.